instruction
stringclasses 1
value | input
stringlengths 104
436
| output
stringlengths 45
55
| text
stringlengths 247
577
|
|---|---|---|---|
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI), Phase 3, Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI), Phase 3, Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI), Phase 3 | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI), Phase 3
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Proteasome Inhibitors (PI) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Proteasome Inhibitors (PI)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3 | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI), Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI), Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Phase 3, Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Phase 3, Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI), Phase 3 | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI), Phase 3
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM), Phase 3, Proteasome Inhibitors (PI) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM), Phase 3, Proteasome Inhibitors (PI)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Phase 3 | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Phase 3
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3 | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM), Phase 3 | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM), Phase 3
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI), Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI), Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Phase 3, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Phase 3, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Phase 3, Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Lenalidomide+Dexamethasone (Rd), Phase 3, Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd), Lenalidomide+Dexamethasone (Rd), Phase 3 | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd), Lenalidomide+Dexamethasone (Rd), Phase 3
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Lenalidomide+Dexamethasone (Rd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Lenalidomide+Dexamethasone (Rd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3 | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd), Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd), Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Lenalidomide+Dexamethasone (Rd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Lenalidomide+Dexamethasone (Rd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Phase 3, Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Phase 3, Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd), Phase 3 | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd), Phase 3
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM), Phase 3, Lenalidomide+Dexamethasone (Rd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM), Phase 3, Lenalidomide+Dexamethasone (Rd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Phase 3 | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Phase 3
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Lenalidomide+Dexamethasone (Rd), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Lenalidomide+Dexamethasone (Rd), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3 | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM), Phase 3 | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM), Phase 3
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd), Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd), Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd), Lenalidomide+Dexamethasone (Rd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd), Lenalidomide+Dexamethasone (Rd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Phase 3, Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Phase 3, Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Phase 3, Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Proteasome Inhibitors (PI), Phase 3, Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd), Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd), Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Lenalidomide+Dexamethasone (Rd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Lenalidomide+Dexamethasone (Rd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM), Proteasome Inhibitors (PI)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Lenalidomide+Dexamethasone (Rd), Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd), Lenalidomide+Dexamethasone (Rd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd), Lenalidomide+Dexamethasone (Rd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide+Dexamethasone (Rd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Proteasome Inhibitors (PI), Ixazomib+Lenalidomide+Dexamethasone (IRd), Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd), Relapsed Refractory Multiple Myeloma (RRMM), Ixazomib+Lenalidomide+Dexamethasone (IRd)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |
Identify the study with the following condition. | Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM) | Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 | ### Instruction:
Identify the study with the following condition.
### Input:
Lenalidomide Not-Refractory, 1,2,3 prior line of therapy, Phase 3, Proteasome Inhibitors (PI), Lenalidomide+Dexamethasone (Rd), Ixazomib+Lenalidomide+Dexamethasone (IRd), Relapsed Refractory Multiple Myeloma (RRMM)
### Output:
Popular Name is TOURMALINE-MM1, Study ID is NCT01564537 |